ReviewCurrent pharmaceutical design2015
Antimicrobial peptides and peptidomimetics - potent therapeutic allies for staphylococcal infections.
Review in Current pharmaceutical design, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 67 citations in OpenAlex.
- Targeting Bacterial Infections in Periodontal Disease: From Conventional Antibiotics to Next-Generation Therapeutics.Antibiotics (Basel, Switzerland) · 2026Review
- Antimicrobial peptides: natural templates for next-generation therapeutics against antimicrobial resistance.Frontiers in cellular and infection microbiology · 2025Review
- Uncovering the Antibacterial Potential of a Peptide-Rich Extract of Edible Bird's Nest againstJournal of microbiology and biotechnology · 2024Article
- Antimicrobial Properties and Cytotoxicity of LL-37-Derived Synthetic Peptides to Treat Orthopedic Infections.Antibiotics (Basel, Switzerland) · 2024Article
- Article
- The activity of antimicrobial peptoids against multidrug-resistant ocular pathogens.Contact lens & anterior eye : the journal of the British Contact Lens Association · 2024Article
- LL37-Derived Fragments Improve the Antibacterial Potential of Penicillin G and Ampicillin against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Combatting persister cells: The daunting task in post-antibiotics era.Cell insight · 2023Review
- The pharmacokinetic-pharmacodynamic modelling framework as a tool to predict drug resistance evolution.Microbiology (Reading, England) · 2023Article
- The current research status and strategies employed to modify food-derived bioactive peptides.Frontiers in nutrition · 2022Review
- The Emerging Role of Probiotics and their Derivatives against Biofilm-Producing MRSA: A Scoping Review.BioMed research international · 2022Article
- Antibacterial Activity of Small Molecules Which Eradicate Methicillin-ResistantFrontiers in microbiology · 2022Article
- Enhancement of Antibiofilm Activity of Ciprofloxacin againstAntibiotics (Basel, Switzerland) · 2021Article
- Alternative Therapeutic Interventions: Antimicrobial Peptides and Small Molecules to Treat Microbial Keratitis.Frontiers in chemistry · 2021Review
- Lactoferrin Functionalized Biomaterials: Tools for Prevention of Implant-Associated Infections.Antibiotics (Basel, Switzerland) · 2020Review
- Mini Review on Antimicrobial Peptides, Sources, Mechanism and Recent Applications.Protein and peptide letters · 2020Review
- Short tryptophan- and arginine-rich peptide shows efficacy against clinical methicillin-resistant Staphylococcus aureus strains isolated from skin and soft tissue infections.Scientific reports · 2019Article
- Second-generation aryl isonitrile compounds targeting multidrug-resistant Staphylococcus aureus.Bioorganic & medicinal chemistry · 2019Article
- Antimicrobial approaches in the prevention of Staphylococcus aureus infections: a review.The Journal of antimicrobial chemotherapy · 2019Review
- The bactericidal effect of lysostaphin coupled with liposomal vancomycin as a dual combating system applied directly on methicillin-resistantInternational journal of nanomedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The pervasiveness of bacterial resistance to conventional antibiotics, particularly those associated with staphylococcal infections, has become a global epidemic. However, research involving antimicrobial peptides (AMPs) and their synthetic analogues has unearthed a potentially novel class of antibacterials for the treatment of an array of diseases caused by pathogenic bacteria, such as staphylococci. AMPs have several unique advantages over traditional antibiotics such as the projected slow emergence of bacterial resistance to these agents and their capability to modulate the host immune response to infection. Unfortunately, their susceptibility to proteolytic degradation, loss of antimicrobial activity due to serum binding or physiological concentration of salts, and toxicity to host tissues has limited their use as systemic agents thus far. Additionally, the presence of economic and regulatory obstacles has hindered the translation of AMPs, as antimicrobials, from the bench to the clinic. The present review delves further into the benefits and challenges of utilizing AMPs as antibacterial agents (particularly for staphylococcal infections), the methods which have been utilized to overcome their limitations, their successes and failures in clinical trials, and future avenues for researchers to pursue to develop AMPs as novel therapeutic allies in the treatment of bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.